Novel biomarkers in acute heart failure

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 206-211

  Yanavitski, Marat ^a   Givertz, Michael M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adiponectin; Biomarkers; CgA; Chromogranin A; Cystatin C; Endoglin; Galectin 3; Heart failure; Leptin; Midregional pro adrenomedullin; MRproADM; Neutrophil gelatinase associated lipocalin; NGAL; Resistin; ST2

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOLOGICAL MARKER; CHROMOGRANIN A; CREATININE; CYSTATIN C; ENDOGLIN; GALECTIN 3; LEPTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PRO ADRENOMEDULLIN; RESISTIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; CARDIORENAL SYNDROME; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DISEASE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; ACUTE-PHASE PROTEINS; ADIPONECTIN; ADRENOMEDULLIN; ANTIGENS, CD; BIOLOGICAL MARKERS; CHROMOGRANIN A; CYSTATIN C; GALECTIN 3; HEART FAILURE; HUMANS; LEPTIN; LIPOCALINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RESISTIN;

EID: 80055030403     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0065-5     Document Type: Article

References (45)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Koelling TM, Chen RS, Lubwama RN, et al. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J. 2004;147:74-78. (Pubitemid 38037400)
3. Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352-360. (Pubitemid 29070149)
4. Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-418.
5. Braunwald E: Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159.
6. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961-2966. (Pubitemid 35424749)
7. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721-726. (Pubitemid 36222600)
8. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549. (Pubitemid 46871338)
9. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607-613. (Pubitemid 47199007)
10. Manzano-Fernández S, Mueller T, Pascual-Figal D: Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259-267.
11. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52:1458-1465.
12. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027-19030.
13. Kapur NK, Heffernan KS, Yunis AA, et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106:1770-1776.
14. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128. (Pubitemid 39492008)
15. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-1224. (Pubitemid 44345127)
16. de Boer RA, Lok DJA, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68.
17. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826-832.
18. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811-817.
19. Shah RV, Givertz MM. Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome. Curr Heart Fail Rep. 2009;6:176-181.
20. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173-179. (Pubitemid 46105715)
21. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268-271. (Pubitemid 40094736)
22. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28:1841-1847. (Pubitemid 47236639)
23. Alehagen U, Dahlström U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354-360.
24. Manzano-Fernández S, Januzzi JL Jr, Boronat-Garcia M, et al. β-Trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol. 2011;57:849-858.
25. Yndestad A, Landro L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;10:1229-1236.
26. Aghel A, Shrestha K, MullensW, et al. Serum neutrophil gelatinaseassociated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16:49-54.
27. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers. Circ J. 2010;74:1274-1282.
28. Potocki M, Breidthardt T, Reichlin T, et al. Midregional proadrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13:R122. Epub 2009 Jul 23.
29. Adlbrecht C, Hulsmann M, Strunk G, et al. Prognostic value of plasma midregional proadrenomedullin and C-terminal-pro-endothelin- 1 in chronic heart failure outpatients. Eur J Heart Fail. 2009;11:361-366.
30. Maisel A, Mueller C, Nowak R, et al.: Mid-region prohormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart failure) trial. J Am Coll Cardiol. 2010;55:2062-2076.
31. Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28:1117-1127. (Pubitemid 47343865)
32. Gupta S, Drazner M, de Lemos J. Newer biomarkers in heart failure. Heart Fail Clin. 2009;5:579-588.
33. Dieplinger B, Gegenhuber A, Struck J, et al. Chromogranin A and Cterminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta. 2009;400:91-96.
34. Jansson A, Røsjø H, Omland T. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2009;30:25-32.
35. Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem. 2010;43:714-719.
36. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756-1762. (Pubitemid 41372115)
37. Matsumoto M, Lee-Kawabata M, Tsujino T, et al. Decrease in serum adiponectin levels in response to treatment predicts good prognosis in acute decompensated heart failure. J Clin Hypertens (Greenwich). 2010;12:900-904.
38. McGaffin K, Witham W, Yester K, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res. 2011;89:60-71.
39. McGaffin K, Moravec C, McTiernan C. Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail. 2009;2:676-683.
40. LiebW, Sullivan L, Harris T, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care. 2009;32:612-616.
41. Murdoch DR, Rooney E, Dargie HJ, et al. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart. 1999;82:352-356. (Pubitemid 29429611)
42. Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure- A novel link between metabolic signals and heart failure. Circ J. 2007;71:460-464.
43. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Serum resistin concentrations and risk of new onset heart failure in older persons: The Health, Aging, and Body Composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009;29:1144-1149.
44. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail. 2011;17:24-30.
45. O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol. 2010;7:13-20.